Mechanism of action
Naloxone is a competitive antagonist at opioid receptors, with highest affinity for mu (μ) receptors, followed by kappa (κ) and delta (δ) receptors. It displaces opioid agonists from these receptors, rapidly reversing opioid-mediated effects including respiratory depression, sedation, miosis, and analgesia.
The drug has no intrinsic agonist activity at opioid receptors, making it a pure antagonist. By blocking mu receptors in the central nervous system, naloxone restores normal respiratory drive within minutes of administration. The competitive nature of this antagonism means that in cases of high opioid concentrations or long-acting opioids, repeat dosing may be necessary.
Naloxone does not reverse benzodiazepine or alcohol toxicity, as these act on different receptor systems. Its selectivity for opioid receptors makes it both highly effective for opioid reversal and diagnostically useful in distinguishing opioid from non-opioid causes of altered mental status.
- Naloxone is a pure competitive antagonist at mu, kappa, and delta opioid receptors with no agonist activity
- Duration of action (30-90 min) is shorter than most opioids, creating renarcotization risk requiring prolonged monitoring
- Precipitates acute opioid withdrawal syndrome in dependent patients, causing sympathetic surge and potential cardiovascular complications
- Titrate to restore adequate respiratory drive (RR >10/min), not full consciousness, to minimize withdrawal
- Oral bioavailability is nearly zero due to extensive first-pass metabolism; must be given parenterally
- Does not reverse benzodiazepine, alcohol, or clonidine toxicity—selective for opioid receptors only
- Intranasal naloxone (4 mg) is effective for bystander administration in community overdose settings
- Relatively contraindicated in neonates of opioid-dependent mothers due to risk of severe withdrawal and seizures
Indications
The primary indication for naloxone is emergency treatment of known or suspected opioid overdose, characterized by respiratory depression, altered mental status, and miosis. It is used in both prehospital and hospital settings to reverse life-threatening opioid toxicity.
Other indications include:
- Postoperative opioid-induced respiratory depression when non-invasive interventions are insufficient
- Reversal of opioid effects in neonates born to mothers who received opioids during labor
- Diagnostic tool to differentiate opioid from non-opioid causes of coma or respiratory depression
- Opioid-induced pruritus in some clinical contexts
- Septic shock (investigational use, mechanism unclear)
Naloxone is available in intranasal, intramuscular, intravenous, and subcutaneous formulations. Intranasal naloxone has become widely available for community-based overdose response, including prescription or distribution to patients at risk and their families.
Pharmacokinetics
Naloxone undergoes extensive first-pass hepatic metabolism, resulting in very low oral bioavailability (approximately 2-3%), which is why parenteral routes are used for acute reversal. The drug is metabolized primarily by glucuronidation in the liver to naloxone-3-glucuronide, an inactive metabolite.
Key pharmacokinetic parameters:
| Parameter | Value |
|---|---|
| Onset of action (IV) | 1-2 minutes |
| Onset of action (IM/SC) | 2-5 minutes |
| Onset of action (intranasal) | 3-8 minutes |
| Duration of action | 30-90 minutes |
| Half-life | 30-90 minutes |
| Metabolism | Hepatic glucuronidation |
| Excretion | Renal |
The short duration of action is clinically critical because many opioids (morphine, methadone, sustained-release formulations) have much longer half-lives than naloxone. This creates the risk of renarcotization—patients may initially respond to naloxone but then become re-sedated as naloxone wears off while opioid effects persist. This necessitates prolonged observation (minimum 4-6 hours) after naloxone administration, particularly with long-acting opioids.
Intranasal naloxone achieves therapeutic levels comparable to intramuscular administration, making it suitable for bystander use in community settings.
Adverse effects
The most significant adverse effect of naloxone is acute opioid withdrawal syndrome in patients with physical opioid dependence. Withdrawal symptoms can begin within minutes and include:
- Agitation, anxiety, irritability
- Nausea, vomiting, diarrhea
- Tachycardia, hypertension
- Diaphoresis, piloerection
- Mydriasis
- Body aches, tremor
- Lacrimation, rhinorrhea
While opioid withdrawal is extremely uncomfortable, it is not life-threatening in adults. However, the associated sympathetic surge can be dangerous in patients with cardiovascular disease, potentially causing:
- Ventricular arrhythmias
- Acute pulmonary edema
- Hypertensive crisis
- Myocardial ischemia or infarction
- Seizures (rare)
Neonates born to opioid-dependent mothers are at particular risk for severe withdrawal when given naloxone, which can precipitate seizures.
Other adverse effects include:
- Pain (reversal of analgesia)
- Nausea and vomiting (even in non-dependent individuals)
- Hypotension or hypertension
- Cardiac arrest (rare, usually in context of underlying cardiac disease)
To minimize withdrawal symptoms while achieving adequate reversal, naloxone should be titrated to effect—giving just enough to restore adequate respiratory drive rather than complete reversal of all opioid effects. The goal is a respiratory rate greater than 10 breaths per minute and adequate oxygenation, not necessarily full alertness.
Contraindications and warnings
Naloxone has no absolute contraindications in the setting of life-threatening opioid overdose, as the benefit of reversing respiratory depression outweighs any risk. Known hypersensitivity to naloxone is a relative contraindication but should not prevent use in emergency situations.
Warnings and precautions:
Opioid dependence: Use with extreme caution in known or suspected opioid-dependent patients. Consider lower initial doses and slow titration to minimize acute withdrawal. However, in the setting of severe respiratory depression, life-saving reversal takes priority over withdrawal concerns.
Cardiovascular disease: The sympathetic surge from acute opioid reversal can precipitate cardiac complications in patients with coronary artery disease, hypertension, or arrhythmias. Monitor cardiovascular parameters closely.
Neonates: Naloxone is relatively contraindicated in neonates of opioid-dependent mothers unless severe respiratory depression is life-threatening and unresponsive to other measures. Prefer ventilatory support when possible to avoid precipitating neonatal withdrawal.
Renarcotization risk: All patients require prolonged monitoring after naloxone administration. The duration of observation should be based on the half-life of the ingested opioid—minimum 4-6 hours, longer for sustained-release or long-acting opioids like methadone.
Postoperative use: When reversing postoperative opioid effects, use minimum effective doses to avoid reversing analgesia completely and causing severe pain, tachycardia, and hypertension.
Pregnancy category: Naloxone is generally considered safe in pregnancy when used for opioid overdose, as maternal death or severe hypoxia poses greater fetal risk. It is classified as pregnancy category C (animal studies show adverse effects; human data limited).
Drug interactions
Naloxone has minimal direct pharmacokinetic drug interactions because it is not metabolized by cytochrome P450 enzymes and does not significantly affect other drugs' metabolism. However, pharmacodynamic interactions are clinically important:
Opioid agonists: Naloxone directly antagonizes all opioid agonists including morphine, fentanyl, heroin, oxycodone, hydromorphone, methadone, and codeine. The degree of reversal depends on the relative doses and receptor affinities. Partial agonists like buprenorphine may be more difficult to reverse due to high receptor affinity.
Mixed agonist-antagonists: Drugs like pentazocine, butorphanol, and nalbuphine have their agonist effects reversed by naloxone.
Clonidine: While not a direct interaction, clonidine overdose can mimic opioid toxicity (miosis, sedation, respiratory depression). Naloxone will not reverse clonidine effects, which can help diagnostically distinguish the two conditions.
No dosage adjustments of naloxone are required based on other medications. However, clinicians should be aware that patients on long-acting opioids (methadone, extended-release formulations) or highly lipophilic opioids (fentanyl) may require higher or repeated doses of naloxone.
There are no significant interactions with alcohol, benzodiazepines, or other sedatives, though these are commonly co-ingested with opioids. Naloxone will not reverse non-opioid causes of respiratory depression.
Clinical pearls
Titrate to respiratory effect, not consciousness. The goal is adequate ventilation (respiratory rate >10/min, oxygen saturation >90%), not full alertness. Overtitration increases withdrawal risk without additional benefit.
Duration mismatch is critical. Naloxone's 30-90 minute duration is much shorter than most opioids. A patient who "wakes up" after naloxone can deteriorate again within an hour. Extended observation is mandatory, and some patients require continuous naloxone infusion.
Intranasal formulation (4 mg) is designed for bystander use and is as effective as IM injection for prehospital overdose reversal. It has enabled widespread community distribution.
Buprenorphine overdose is particularly challenging because buprenorphine has very high mu receptor affinity. Much higher naloxone doses may be required, and respiratory support may be needed.
Diagnostic value: Failure to respond to adequate naloxone dosing suggests either a non-opioid cause of altered mental status, co-intoxication with other sedatives, or structural brain injury. Consider alternative diagnoses.
Body packer syndrome: Patients who swallow drug packets for smuggling may have massive opioid release if packets rupture. These patients may require very large naloxone doses and continuous infusion.
Withdrawal is not an excuse to withhold naloxone in life-threatening overdose. While uncomfortable, withdrawal will not kill an adult patient, but respiratory failure will.
Multi-dose vials of naloxone often contain methylparaben or propylparaben preservatives. Single-dose formulations are preferred for neonates.
Consider the source: Illicit fentanyl and its analogs are increasingly prevalent. These potent synthetic opioids may require higher or repeated naloxone doses compared to traditional opioids like heroin.
Practice questions
1. A 28-year-old man is brought to the emergency department unresponsive. He has pinpoint pupils, a respiratory rate of 6/min, and oxygen saturation of 82% on room air. His friends report he was using heroin. After establishing an airway and providing supplemental oxygen, 2 mg of intravenous naloxone is administered. Within 2 minutes, the patient becomes alert, agitated, and combative. Vital signs are: temperature 37.2°C, pulse 118/min, respirations 24/min, blood pressure 168/98 mmHg. He is diaphoretic and reports severe body aches and nausea. Which of the following best explains this patient's current presentation?
2. A 35-year-old woman undergoes an emergency cesarean section under general anesthesia with fentanyl for analgesia. Postoperatively, she is somnolent with a respiratory rate of 8/min and oxygen saturation of 88% on room air. After naloxone administration, her respiratory rate improves to 14/min, but she reports severe incisional pain rated 9/10. Vital signs show pulse 112/min and blood pressure 158/92 mmHg. What is the most appropriate next step in management?
3. A 42-year-old man with chronic pain is found unresponsive by his family. Emergency medical services administer intranasal naloxone, and he wakes up briefly but becomes lethargic again within 45 minutes. He is on a buprenorphine patch for chronic pain management. Which of the following best explains the clinical course?
Frequently asked questions
How does naloxone work?
Naloxone works by competitively binding to opioid receptors in the brain and body, displacing opioid drugs and rapidly reversing their effects. It has highest affinity for mu opioid receptors, which mediate respiratory depression and sedation. Within 1-2 minutes of intravenous administration, naloxone restores normal breathing and consciousness in opioid overdose. Because it is a pure antagonist with no agonist activity, it produces no opioid-like effects on its own.
What are the side effects of naloxone?
The main side effect of naloxone is acute opioid withdrawal syndrome in people who are physically dependent on opioids. Withdrawal symptoms include agitation, nausea, vomiting, body aches, sweating, rapid heart rate, and elevated blood pressure. This sympathetic surge can be dangerous in patients with heart disease, potentially causing arrhythmias, pulmonary edema, or heart attack. In people without opioid dependence, side effects are minimal but may include nausea and return of pain if opioids were being used for analgesia.
Is naloxone a controlled substance?
No, naloxone is not a controlled substance in the United States or most other countries. Because it has no abuse potential and produces no euphoric effects, it is not scheduled under the Controlled Substances Act. This lack of scheduling has facilitated widespread distribution of naloxone to community members, first responders, and family members of people at risk for opioid overdose. Many jurisdictions now allow pharmacists to dispense naloxone without a prescription.
How long does naloxone last?
Naloxone typically lasts 30 to 90 minutes after administration, which is much shorter than most opioids. This creates a critical clinical problem called renarcotization, where a patient initially wakes up after receiving naloxone but then becomes sedated again as the naloxone wears off while the opioid is still active. For this reason, all patients who receive naloxone require extended monitoring for at least 4-6 hours, and longer if they took long-acting opioids like methadone or sustained-release formulations.
Naloxone vs naltrexone — what is the difference?
Both naloxone and naltrexone are opioid antagonists, but they differ in pharmacokinetics and clinical use. Naloxone has a very short duration (30-90 minutes) and is used for acute emergency reversal of opioid overdose. Naltrexone has a much longer duration (24-72 hours with daily dosing, or 30 days for the monthly injection) and is used for long-term treatment of opioid use disorder and alcohol use disorder. Naloxone has virtually no oral bioavailability, while naltrexone is orally active.
Conditions it is used for
Related drugs
Sources and further reading
DailyMed (FDA labels)StatPearls (NCBI Bookshelf)MedlinePlusWHO ATC/DDD index: A06AH04WHO ATC/DDD index: V03AB15
Educational content for medical students, prepared by the WhiteCoat Pro editorial team with AI assistance; every page is reviewed by a second AI model for factual errors. It is not medical advice and does not replace the product label, local guidelines or a clinician.